Sugi Predict

Sugi Predict / Compounds / SCHEMBL14427861

SCHEMBL14427861

SCHEMBL14427861

COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCOCC1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.87
▸ ERBB2 P04626 13/20 0.82
▸ ERBB4 Q15303 9/20 0.82
▸ GAK O14976 2/20 0.76
▸ RIPK2 O43353 2/20 0.76
▸ LCK P06239 2/20 0.76
▸ SRC P12931 2/20 0.76
▸ JAK3 P52333 2/20 0.76
▸ RIPK3 Q9Y572 2/20 0.76
▸ NR1I2 O75469 1/20 0.76
▸ ADORA3 P0DMS8 1/20 0.76
▸ CHRM1 P11229 1/20 0.76
▸ DRD2 P14416 1/20 0.76
▸ ADRA2C P18825 1/20 0.76
▸ SLC6A2 P23975 1/20 0.76
▸ MC3R P41968 1/20 0.76
▸ SLC6A3 Q01959 1/20 0.76
▸ PDE4D Q08499 1/20 0.76
▸ KCNH2 Q12809 1/20 0.76
▸ BMPR1B O00238 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14066626 0.93 EGFR (0.87) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL14427862 0.93 EGFR (0.95) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL14427860 0.93 EGFR (0.81) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL30115324 0.91 EGFR (0.88) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL22277127 0.91 EGFR (0.88) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL33143 0.90 EGFR (1.00) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL30115330 0.90 EGFR (1.00) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL14427865 0.90 EGFR (0.78) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL19100270 0.90 EGFR (0.80) EGFRERBB2ERBB4GAKRIPK2
SCHEMBL14066632 0.89 EGFR (0.77) EGFRERBB2ERBB4GAKRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185081-A1 Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-09 — — US disclosed
US-20070185081-A1 Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-09 — — US disclosed
US-7223749-B2 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-29 — — US disclosed
US-7223749-B2 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185081-A1 Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them RET, AR, RB1 EGFR 263/4885ERBB2 140/4885ERBB4 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.